21 May 2013
Keywords: amrad, halts, work, neuropathy, drug, australian, development
Article | 29 April 2002
Australian drug development company Amrad has abandoned work on a drugdesigned to reduce nerve damage during cancer treatment. The firm ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 April 2002
20 May 2013
© 2013 thepharmaletter.com